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cardiographic findings. Accurate diagnosis by immediate coronary angio-
graphy can be followed in suitable candidates by coronary angioplasty, which
seems to improve survival.
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Background: Stenting options for patients at high risk of bleeding
(elderly, AF, ACS) are sub-optimal. BMS are not as effective as DES in
reducing restenosis but DES require long term DAPT, which increases
bleeding risk. Recent animal studies have demonstrated that the nano PzF sur-
face modified stent (Cobra PzF, CeloNova) is thrombo-resistant, and is asso-
ciated with a rapid reendothelialization.
Method: 100 patients (71 men) with mean age 71.4±2 year old of all
comer patients were prospectively included to evaluate the safety and the effi-
cacy of the Cobra PzF stent. Patients presented with multiple co-morbidities
including 22% DM, 10% AF, 17% EF<40%, 10% VKA, 28% ACS, 10%
STEMI and 26% diffused and multivessel diseases.
Results: 166 Cobra PzF stents were implanted in 151 lesions (74% B1
lesions) via a radial route (72%) with a 6F-guiding catheter. 1.66 stent/pt was
implanted for a mean stent length of 18.7± 0.5mm and a mean diameter of
3.1±0.3mm. Target lesions in left main (2%), LAD Diag (43%), CxMg (23%),
RCA (32%), including bifurcated kissed lesions (12%) were treated with 50%
direct stenting. The device was successfully implanted in 100% of targeted
lesions to achieve a complete revascularization in all cases. In-hospital, there
were no adverse events (Death, MI, TLR, cerebral events, stent thrombosis) or
incidence of major bleeding complications or transfusions. At one month, no
events were reported. 6-month results showed 4% of MACE (terminal cardiac
insufficiency and 3 restenosis successfully treated).
Conclusion: Those Results are very promising in real world and complex
patients (Diabetes, AF, Acute MI, Unstable Angina, Bifurcation, VKA). The
COBRA PzF stent is safe and effective in routine practice. These preliminary
data and the rapid reendothelialization observed in preclinical will serve as an
impetus for a multi-center randomized study of short DAPT.
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Between february 2013 and april 2014, of 1450 coronary angioplaty procé-
dures realized in our institution, 65 patients, aged 64.3 (40-94), underwent
coronary artery stenting with Absorb Biovascular Scaffold (BVS)
Clinical data: exercise angina 22 patients, acute coronary syndromes 37
(including acute myocardial infarction 5), silent ischemia 7, heart failure 2.
Ten patients suffered diabètes (15%) and 14 experienced previous coronay
interventions (20%).
Procedural data: all stents have been implanted under angiographic
control (except two cases including IVUS imaging) in de novo lésions through
a radial approach with 6F guiding catheters following mandatory predilatation.
44 patients had single vessel desease (67%) and 21 multivessel desease.
Target vessel was the left anterior descending artery in 35 cases, left circum-
flex in 10 and right artery in 14. 68 stents have been delivered; three patients
had two BVS; 16 patients had also metallic drug eluting stents in other
arteries. Side branch dilatation had to be performed in 4 patients. Implantation
was successfull in all cases. 
In hospital follow up: No death Complications: side branch occlusion
with non Q wave infarction in one case and transient ischaemic attack in one
another. 58 patients left the institution the day after the procedure under con-
ventionnal dual antiplatelet therapy. 
Out hospital follow up: at 6.2 month (1-15) all patients were event free
(100%) Three patients had angiographic control at one year and were free of
restenosis; one another had 70% angiographic restenosis at the edges of the
stent and underwent longer DES implantation (TLR: 1.5%). Three other
patients had computed tomography scanner control at one year with no evi-
dence of restenosis, including one case demonstrating restoration of systolic
compression of the stented segment in a myocardal bridging whereas diastolic
diameter was normal.
Conclusions: at that time our preliminary data confirm the safety of the
BVS device at implantation and at six months follow up.
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Purpose: This study sought to study the second-generation everolimus-
eluting stent (EES) as compared with first-generation sirolimus-eluting (SES)
in diabetes mellitus (DM) patients.
Methods: All DM patients treated with EES or SES from January 2010, to
December 2011 were included. The EES was compared with SES for the pri-
mary composite endpoint of clinically driven detected restenosis, definite stent
thrombosis (ST), and all-cause mortality.
Results: In 226 percutaneous coronary intervention-treated DM patients,
353 stents were implanted (EES 118, SES 235). The EES was associated with
significantly lower restenosis rates compared with SES (SES vs. EES: 16.7%
vs. 2.8%, p=0,001, OR: 2.96; 95% CI: 1.57 to 5.57). Lower incidence of ST
(SES vs. EES: 2,1% vs 0,8%, p=0,38) and mortality (SES vs. EES: 1,7 % vs
0%, p=0,15) was noted but did not reach statistical significance. 
Conclusions: In all-comer DM patients the use of EES was associated with
improved outcomes compared with SES mainly driven by lower rates of clin-
ically driven detected restenosis.
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Purposes: The aim of this study was to evaluate one-year incidence of
bleeding events and their impact on compliance in patients admitted for ST
Elevation Myocardial Infarction (STEMI) and treated by prasugrel or clopido-
grel in « real-world ». 
Methods: Patients admitted for a STEMI were treated by either clopido-
grel or prasugrel according to the physician with respect of guidelines. The
primary endpoint was the first occurrence of bleeding events within 12 months
assessed by the Bleeding Academic Research Consortium (BARC) classi-
fication using a dedicated questionnaire focused on bleeding events. Topo-
graphy bleedings, causes of premature cessation and ischemic events were
also compared. 
Results: 390 patients were enrolled, 211 in prasugrel group and 179 in
clopidogrel group. Patients in the prasugrel group were younger, with higher
